Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of “Buy” from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given an average rating of “Buy” by the nine ratings firms that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $13.13.

A number of research firms have commented on CMPX. Guggenheim reduced their price objective on Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th.

Insider Buying and Selling at Compass Therapeutics

In other news, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The stock was bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the insider now directly owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 29.80% of the company’s stock.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently modified their holdings of the stock. Birchview Capital LP acquired a new stake in shares of Compass Therapeutics in the 1st quarter valued at approximately $46,000. Propel Bio Management LLC acquired a new stake in Compass Therapeutics in the first quarter worth $434,000. Walleye Trading LLC acquired a new stake in Compass Therapeutics in the first quarter worth $48,000. Walleye Capital LLC bought a new position in shares of Compass Therapeutics during the first quarter worth $100,000. Finally, Wellington Management Group LLP acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at $423,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Down 0.5%

Shares of Compass Therapeutics stock opened at $2.09 on Thursday. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market capitalization of $289.01 million, a P/E ratio of -5.65 and a beta of 1.40. The company has a 50-day simple moving average of $1.90 and a 200 day simple moving average of $2.12.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). On average, equities analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.